WeTrials
Active, not recruiting

A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of TNG260 as Single Agent and in Combination With an Anti-PD-1 Antibody In Patients With STK11 Mutated Advanced Solid Tumors

What is this study?

This clinical trial is testing a new experimental medication called TNG260, both alone and combined with an immunotherapy drug called pembrolizumab. Researchers want to find the safest and most effective dose to help patients with advanced solid tumors that have a specific genetic change known as an STK11 mutation.

Who can participate?

You may be able to join if you are 18 or older, can handle daily activities well, and have an advanced solid tumor—such as lung cancer—that tests positive for the STK11 genetic change. Participants must also be free of severe allergies to the study drugs and have no other uncontrolled medical conditions.

What will happen?

Participants will receive the study treatment until the medication becomes unsafe, side effects are too strong, or the cancer grows. Doctors will closely monitor your health, check how your body processes the drug, and see how well the treatment fights the cancer.

Where and when?

This study is currently active and not recruiting new patients at locations in California, Colorado, and Florida in the United States.

Key Points
  • 1Tests the new drug TNG260 combined with pembrolizumab for advanced cancers.
  • 2Specifically designed for patients whose tumors have an STK11 genetic mutation.
  • 3Currently active but not enrolling new participants at select US locations.

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Non Small Cell Lung CancerSolid Tumors, AdultLung CancerLung Adenocarcinoma

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.